Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2) antagonist with potential antineoplastic activity owing to increase in p53 activity through interruption of the MDM2‐p53 interaction. This phase I, dose‐escalating study assessed the safety, tolerability, efficacy, an...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Takahashi, Shunji, Fujiwara, Yutaka, Nakano, Kenji, Shimizu, Toshio, Tomomatsu, Junichi, Koyama, Takafumi, Ogura, Mariko, Tachibana, Masaya, Kakurai, Yasuyuki, Yamashita, Tomonari, Sakajiri, Sakura, Yamamoto, Noboru
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2021
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177775/
https://ncbi.nlm.nih.gov/pubmed/33686772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14875
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi